Shares: Drug cure for depression: Quentin Lumsden prescribes six healthcare stocks set for recovery
Sunday 06 September 1992
One problem with the leading healthcare stocks is that they are much favoured by institutional investors and tend to have heavyweight share prices.
In terms of its price-earnings ratio, the cheapest of the six international drug shares I have selected for my mini-portfolio is the Swiss group Roche, which is on a prospective p/e for 1993 of under 13, according to the analyst Andrew Tivenen, of James Capel. But one share in Roche costs a jaw-dropping SFr3,380 (pounds 1,368).
Fortunately, heavyweight prices are no bar to a sizzling performance. Roche shares have climbed four-fold from their levels in the mid-1980s. The same goes for the other shares in my selection. Glaxo at 749p is up five-fold; Wellcome, at 826p, is up 6.5 times. The world's leading drug company, Merck, at dollars 48.25 (pounds 24.14), is up 10 times in dollar terms but nearer 5.5 times for sterling-based investors. Pfizer, at dollars 79.62, also based in the US, was a slow starter in the 1980s, but new drugs have boosted it around 2.5 times in sterling. Lastly, the Swedish company Astra, at Kr535 for the 'A' shares, has grown fastest of all: 8.5 times in sterling terms.
The key attraction of these great healthcare companies is their ability to sustain strong growth in earnings despite recession. The analysts at James Capel suggested the following medium-term growth rates for my selection: Glaxo 14 per cent, Wellcome 20 per cent, Merck 18, Pfizer 19, Astra 25-30 and Roche 20. That looks highly attractive in a world where investors are coming to terms with the prospect that the global economy may stay becalmed into the mid-1990s. A big change in this decade is that the pronounced weakness of the dollar is no longer seen as a negative for European drug stocks, even though they all make a substantial proportion of their sales in the US.
One analyst, Paul Woodhouse at Smith New Court, says observation almost suggests these shares flourish when the dollar is weak. This could be because American investors like to buy strong-currency stocks.
Nor are profits as adversely affected as in the past. Wellcome and other companies manufacture in the US so that they do not have the problem of trying to sell into the US from a high-cost base. Glaxo sources heavily from dollar-bloc areas such as Singapore.
Furthermore, manufacturing costs are only about 16 per cent of final selling prices. Twice as important are sales and marketing costs incurred in the US for sales made there.
A combination of investors neglecting drug shares and general gloom in stock markets has made these pharmaceuticals relatively cheap by historic standards. Astra, for example, has a spectacular portfolio of drugs. Its world-beating ulcer preparation, Losec, has overtaken SmithKline's Tagamet and is second only to Glaxo's Zantac. Yet on analyst Andrew Tivenen's estimates, Astra is on a prospective p/e of 16 on 1993 earnings per share, and could well continue to grow rapidly.
Shares in Wellcome, almost equally fast-growing, have been depressed by the huge shares sale, and the p/e for the year to 31 August next could be below 18. These are undemanding valuations for some of the most exciting and reliable growth stocks.
- 1 Migrant crisis: Greek soldier saved 20 people singlehandedly off Rhodes beach
- 2 Sofyen Belamouadden murder: The inside story of a crime that horrified Britain
- 3 UK weather: Britain braced for snow as arctic air mass moves in
- 5 'Isis' schoolgirls: Missing British teenager tweets picture of her Syrian takeaway
Migrant crisis: Greek soldier saved 20 people singlehandedly off Rhodes beach
Ian Brady: Moors murderer announces his support for Ukip and the SNP
Aaron and Melissa Klein: Oregon anti-gay bakers ordered to pay $135,000 after refusing to make cake for same-sex wedding
UK weather: Britain braced for snow as arctic air mass moves in
Power of Nepal earthquake was equivalent to 20 huge atomic bombs
General Election 2015: Chuka Umunna on the benefits of immigration, humility – and his leader Ed Miliband
The sickening truth about food banks that the Tories don't want you to know
Migrant boat disaster: Ukip candidate mocks victims in sickening Twitter post
Nigel Farage wants the BBC to stop making programmes like Doctor Who, Strictly Come Dancing, and Top Gear
Global warming: Scientists say temperatures could rise by 6C by 2100 and call for action ahead of UN meeting in Paris
General Election 2015: Britain would become a 'communist dictatorship' under Ed Miliband and Nicola Sturgeon, claims wife of Michael Gove
iJobs Money & Business
£20000 - £60000 per annum: Recruitment Genius: Are you recently QCA Level 4 qu...
£20000 - £22500 per annum + OTE £30K: SThree: SThree Group have been well esta...
£25 - 30k: Guru Careers: We are seeking an Application Support Analyst / 1st L...
£45K - £55K (DOE) + Benefits: Guru Careers: We are seeking a full stack .NET D...